Twist Bioscience Corp (TWST)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $7.40B
Last updated: Nov 17, 2026 at 11:06 AM ET
Twist Bioscience Corp (TWST) Financials: Revenue, Profit and Cash Flow
Twist Bioscience reported revenue of $459.43M for the fiscal year ended Sep 30, 2026, up 22.0% from the year before. That year, net income was -$130.20M with a net margin of -28.3%, operating cash flow was -$41.43M and free cash flow was -$89.01M. The quarter ended Sep 30, 2026 had revenue of $126.64M and net income of -$20.62M.
Revenue and Margins
The operating margin was -30.4% in the fiscal year ended Sep 2026, the highest of the 4 years shown with an operating margin. Over the 9 years to Sep 2026, revenue grew from $10.77M, a compound annual rate of 51.7%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Sep 2026 | $459.43M | +22.0% | 52.4% | -30.4% | -28.3% |
| Sep 2025 | $376.57M | +20.3% | 50.7% | -36.2% | -20.6% |
| Sep 2024 | $312.97M | +27.7% | 42.6% | -70.6% | -66.7% |
| Sep 2023 | $245.11M | +20.4% | 36.6% | -88.6% | -83.5% |
| Sep 2022 | $203.56M | +53.8% | 41.4% | -115.3% | -107.0% |
| Sep 2021 | $132.33M | +46.9% | 39.1% | -115.4% | -114.9% |
| Sep 2020 | $90.10M | +65.7% | 31.8% | -155.5% | -155.3% |
| Sep 2019 | $54.38M | +113.9% | 12.8% | -200.1% | -198.0% |
| Sep 2018 | $25.43M | +136.2% | -26.6% | -277.5% | -280.2% |
| Sep 2017 | $10.77M | N/A | -123.1% | -543.2% | -550.8% |
Income Statement
In the fiscal year ended Sep 2026, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.
Annual
| Line item | Sep 2026 | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $459.43M | $376.57M | $312.97M | $245.11M | $203.56M | $132.33M | $90.10M | $54.38M | $25.43M | $10.77M |
| Cost of revenue | $218.63M | $185.57M | $179.63M | $155.38M | $119.33M | $80.62M | $61.41M | $47.43M | $32.19M | $24.02M |
| Gross profit | $240.80M | $191.00M | $133.35M | $89.73M | $84.23M | $51.71M | $28.69M | $6.96M | -$6.76M | -$13.25M |
| Research and development | $71.84M | $80.28M | $90.85M | $106.89M | $120.31M | $69.07M | $43.01M | $35.68M | $20.35M | $19.17M |
| Operating income | -$139.46M | -$136.26M | -$220.83M | -$217.16M | -$234.78M | -$152.73M | -$140.08M | -$108.85M | -$70.56M | -$58.48M |
| Net income | -$130.20M | -$77.67M | -$208.73M | -$204.62M | -$217.86M | -$152.10M | -$139.93M | -$107.67M | -$71.24M | -$59.31M |
| EBITDA | -$112.12M | -$63.46M | -$192.08M | -$188.52M | -$219.35M | -$144.88M | -$133.61M | -$103.97M | -$64.64M | -$53.42M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $126.64M | $118.38M | $110.72M | $103.70M | $99.01M | $96.06M | $92.79M | $88.71M | $84.71M | $81.46M | $75.30M | $71.50M |
| Gross profit | $67.25M | $62.45M | $57.12M | $53.97M | $50.84M | $51.30M | $46.03M | $42.84M | $38.23M | $35.27M | $30.88M | $28.96M |
| Operating income | -$24.41M | -$36.28M | -$45.86M | -$32.90M | -$29.93M | -$30.12M | -$41.56M | -$34.64M | -$36.04M | -$88.92M | -$48.89M | -$46.98M |
| Net income | -$20.62M | -$35.05M | -$44.02M | -$30.51M | -$27.14M | $20.39M | -$39.33M | -$31.59M | -$34.66M | -$85.57M | -$45.49M | -$43.01M |
Balance Sheet
As of Sep 2026, cash and equivalents of $533.99M were 47.7% of total assets of $1.12B, against total liabilities of $233.79M.
Annual
| Line item | Sep 2026 | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.12B | $641.86M | $614.32M | $776.40M | $961.38M | $702.10M | $398.88M | $186.99M | $115.79M | $85.66M |
| Current assets | $737.22M | $332.97M | $346.78M | $424.26M | $596.48M | $546.50M | $334.87M | $160.13M | $95.67M | $67.87M |
| Cash and equivalents | $533.99M | $183.05M | $226.32M | $286.47M | $378.69M | $465.83M | $93.67M | $46.73M | $80.76M | $31.23M |
| Total liabilities | $233.79M | $168.90M | $141.63M | $152.97M | $171.99M | $121.28M | $62.62M | $34.91M | $26.73M | $219.01M |
| Short-term debt | N/A | $13.82M | $14.80M | $14.90M | $13.64M | $1.55M | $3.33M | $3.33M | $2.50M | $9.15M |
| Long-term debt | N/A | N/A | N/A | N/A | N/A | N/A | $1.40M | $4.40M | $7.22M | $9.15M |
| Shareholder equity | $888.02M | $472.96M | $472.69M | $623.43M | $789.38M | $580.82M | $336.26M | $152.08M | -$201.42M | -$133.36M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.12B | $672.44M | $676.21M | $638.09M | $641.86M | $643.61M | $595.62M | $608.58M | $614.32M | $638.12M | $702.85M | $732.82M |
| Total liabilities | $233.79M | $226.70M | $221.12M | $181.99M | $168.90M | $165.41M | $155.51M | $152.64M | $141.63M | $146.98M | $142.72M | $142.77M |
| Cash and equivalents | $533.99M | $117.44M | $122.67M | $148.59M | $183.05M | $201.37M | $210.44M | $221.40M | $226.32M | $239.14M | $243.35M | $266.27M |
| Shareholder equity | $888.02M | $445.74M | $455.09M | $456.10M | $472.96M | $478.20M | $440.11M | $455.94M | $472.69M | $491.14M | $560.13M | $590.04M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Sep 2026.
Annual
| Line item | Sep 2026 | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$41.43M | -$47.63M | -$64.09M | -$142.47M | -$124.39M | -$112.24M | -$142.25M | -$87.94M | -$66.16M | -$51.30M |
| Capital expenditures | $47.58M | $28.00M | $5.08M | $27.78M | $101.86M | $27.06M | $9.87M | $14.76M | $3.69M | $6.59M |
| Free cash flow | -$89.01M | -$75.63M | -$69.17M | -$170.25M | -$226.24M | -$139.31M | -$152.12M | -$102.69M | -$69.85M | -$57.90M |
| Share repurchases | $42.00K | $16.00K | $3.98M | $4.41M | $7.75M | $10.85M | $2.42M | $0 | $2.36M | $0 |
| Investing cash flow | -$53.09M | -$24.76M | -$3.07M | $50.61M | -$232.93M | $156.16M | -$114.65M | -$104.81M | $27.31M | -$9.99M |
| Financing cash flow | $446.68M | $28.54M | $6.89M | $911.00K | $270.53M | $329.18M | $303.73M | $158.58M | $88.82M | $63.80M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$173.00K | $1.11M | -$17.56M | -$24.81M | -$11.81M | -$1.40M | -$12.99M | -$21.43M | -$15.32M | -$6.38M | -$19.42M | -$22.97M |
| Capital expenditures | $14.96M | $9.76M | $12.89M | $9.97M | $12.43M | $9.16M | $4.14M | $2.27M | $2.00M | $965.00K | $603.00K | $1.51M |
| Free cash flow | -$15.13M | -$8.65M | -$30.45M | -$34.79M | -$24.24M | -$10.56M | -$17.13M | -$23.70M | -$17.32M | -$7.34M | -$20.03M | -$24.48M |
Frequently Asked Questions About TWST
What is Twist Bioscience's annual revenue?
Twist Bioscience reported revenue of $459.43M for the fiscal year ended Sep 30, 2026.
How fast is Twist Bioscience's revenue growing?
Revenue was up 22.0% for the fiscal year ended Sep 30, 2026 compared with the year before. The compound annual revenue growth rate over 3 years was 23.3%.
Is Twist Bioscience profitable?
No. Twist Bioscience reported net income of -$130.20M for the fiscal year ended Sep 30, 2026, with a net margin of -28.3%.
How much free cash flow does TWST generate?
For the fiscal year ended Sep 30, 2026, operating cash flow of -$41.43M minus capital expenditures of $47.58M produced free cash flow of -$89.01M.
How much debt does Twist Bioscience have?
The balance sheet dated Sep 30, 2026 reported cash and equivalents of $533.99M.
TWST pages: Overview, Earnings, Forecast, Financials, Competitors, Government Contracts